A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 364 participants.

Also called NCT07923357

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 364 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07923357
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07923357. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-30 (anticipated); primary completion 2027-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Type 2 Diabetes
Condition
T2DM
Intervention (Drug)
SAL0150 dose 1
Intervention (Drug)
SAL0150 dose 2
Intervention (Drug)
SAL0150 dose 2
Intervention (Drug)
SAL0150 dose 3
Intervention (Drug)
SAL0150 dose 3
Intervention (Drug)
Placebo
Intervention (Drug)
Semaglutide inject 1.0 mg
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07923357
Content hash
7d32616a211c54d8a4e216ddef0a242884a7acd01d96f0b9926c793fe75bec42